| 发明名称 | Deuterated baricitinib | ||
| 摘要 | The present invention in one embodiment provides a compound of Formula I:; or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification. | ||
| 申请公布号 | US9540367(B2) | 申请公布日期 | 2017.01.10 |
| 申请号 | US201314422049 | 申请日期 | 2013.08.15 |
| 申请人 | Concert Pharmaceuticals, Inc. | 发明人 | Tung Roger D. |
| 分类号 | C07D487/04;A61K31/519;A61P19/02;A61P35/04;A61P37/06;C07D471/04;A61P29/00;A61P3/10 | 主分类号 | C07D487/04 |
| 代理机构 | McCarter & English, LLP | 代理人 | McCarter & English, LLP ;Davis Steven G. |
| 主权项 | 1. A compound of Formula Ia:or a pharmaceutically acceptable salt thereof, wherein: each of Y1a, Y1b, Y2a and Y2b is hydrogen or each of Y1a, Y1b, Y2a and Y2b is deuterium; X1 and X2 are the same and selected from hydrogen and deuterium; Z1 and Z2 are the same and selected from hydrogen and deuterium; and R is selected from —CH3, —CH2D, —CHD2, and —CD3; provided that when Y1a, Y1b, Y2a, Y2b, X1 and X2 are each hydrogen, and R is —CH3, then at least one of Z1 or Z2 is deuterium. | ||
| 地址 | Lexington MA US | ||